This week on Pharm5:
- Terlivaz (terlipressin) for hepatorenal syndrome
- Pfizer’s mRNA flu vaccine (enroll here: https://bit.ly/3DMRO0r)
- Potential triple-action drug for diabetes or weight loss
- Warfarin use in AFib with rheumatic heart disease
- CVS and Walmart settle; Walgreens heads to court
References
- Terlivaz. Package Insert. Mallinckrodt Pharmaceuticals; 2022.
- Pharmacypracticenews.com. https://bit.ly/3xHxgTm. Published September 15, 2022. Accessed September 22, 2022.
- Biggins SW, Angeli P, Garcia‐Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and Hepatorenal Syndrome: 2021 practice guidance by the American Association for the study of liver diseases. Hepatology. 2021;74(2):1014-1048. doi:10.1002/hep.31884
- Pfizer initiates phase 3 study of mrna-based influenza vaccine. Pfizer. https://bit.ly/3dBgvCx. Published September 14, 2022. Accessed September 22, 2022.
- Mitchel L. Zoler PD. Triple threat: Novel agent shows potent T2D Weight Loss. Medscape. https://wb.md/3SmPWzK. Published September 22, 2022. Accessed September 22, 2022.
- A1C and weight change results: Mounjaro™ (tirzepatide). Mounjaro. https://bit.ly/3DNdutI. Accessed September 22, 2022.
- Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease–associated atrial fibrillation. New England Journal of Medicine. 2022;387(11):978-988. doi:10.1056/nejmoa2209051
- Knauth D. CVS, Walmart reach $147.5 million opioid settlement with West Virginia. Medscape. https://wb.md/3BGNWeK. Published September 22, 2022. Accessed September 22, 2022.
